Group 6C: HER2-low Breast Cancer; Sequencing Antibody-drug Conjugates
Friday, Dec 15
6:00 pm – 7:30 pm Eastern Time (US/New York)
Multicenter retrospective cohort study of the sequential use of the Antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).
Poster author Laura Huppert, M.D. is also the scientist for this session
Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis.
Poster author Rachel Occhiogrosso Abelman, M.D. will attend this session
Mentor: Marlena Murphy
In 2018, Marlena Murphy was diagnosed with stage III triple-negative breast cancer. In 2019, as a volunteer patient advocate for My Style Matters, she attended the San Antonio Breast Cancer Symposium with the very first GRASP poster walkthroughs. Additionally, Marlena serves as a volunteer on the Emory Winship Cancer Institute Patient and Family Advisory (PFA) Council. Because of Marlena’s commitment to advocacy and seeking knowledge beyond the realm of breast cancer, she was offered a position as a Program Manager with GRASP in 2021. Now, she serves as an enthusiastic team member, and coordinates and leads the GRASP Huddles.
Marlena has participated as a DOD Breast Cancer Research Program (BCRP) consumer grant reviewer, and was featured in the 2022 AACR Cancer Disparities Progress Report. She also works as a Community Advocate for TurningPoint Breast Cancer Rehabilitation. Marlena’s role as a patient advocate was one she did not plan on during her lifetime, yet, she accepted it and decided that her diagnosis would not be in vain. Marlena is a mother to a teenage daughter and enjoys helping others. As a result of her diagnosis and desire to help people, Marlena entered grad school in 2020 and became a Clinical Mental Health Counselor in May 2023. Marlena currently provides therapy for individuals experiencing homelessness and will also provide pro bono therapy for breast cancer patients and survivors.
Scientist: Laura Huppert, M.D.
Dr. Laura Huppert is an Assistant Professor and breast medical oncologist at the University of California, San Francisco (UCSF). Dr. Huppert earned her medical degree at Harvard Medical School. She completed Internal Medicine residency and Hematology/Oncology Fellowship at UCSF before starting on faculty at UCSF in July 2022. Dr. Huppert is interested in clinical and translational breast cancer research in both early-stage and metastatic disease. She is involved in the I-SPY2 clinical trial for neoadjuvant therapy in early-stage breast cancer. She is also interested in designing clinical trials with novel therapies for patients with metastatic breast cancer and is the PI of several investigator-initiated clinical trials with novel agents. She also has a particular interest in breast cancer that has metastasized to the central nervous system, and conducts translational research in this space aimed to better identify prevention and treatment strategies.